Danaher (NYSE:DHR) Coverage Initiated by Analysts at DZ Bank

DZ Bank started coverage on shares of Danaher (NYSE:DHR) in a research report issued to clients and investors on Wednesday. The brokerage set a “buy” rating and a $210.00 price target on the conglomerate’s stock. DZ Bank’s price target suggests a potential upside of 19.34% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on DHR. Wells Fargo & Company decreased their target price on Danaher from $240.00 to $212.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 22nd. Evercore boosted their target price on Danaher from $225.00 to $232.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 21st. Royal Bank Of Canada assumed coverage on Danaher in a research note on Thursday, May 14th. They set an “outperform” rating and a $200.00 target price for the company. TD Cowen decreased their target price on Danaher from $245.00 to $240.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Finally, Wall Street Zen cut Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Twenty investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $235.14.

Danaher Stock Performance

Shares of Danaher stock opened at $175.97 on Wednesday. Danaher has a one year low of $160.93 and a one year high of $242.80. The company has a market cap of $124.54 billion, a PE ratio of 34.04, a P/E/G ratio of 2.40 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87. The business has a 50-day simple moving average of $181.91 and a 200-day simple moving average of $207.20.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, April 20th. The conglomerate reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $6 billion. During the same period in the previous year, the company posted $1.88 earnings per share. The business’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, equities research analysts forecast that Danaher will post 8.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Danaher

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp lifted its stake in Danaher by 1.7% in the fourth quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock valued at $6,345,529,000 after buying an additional 472,608 shares during the last quarter. Capital International Investors lifted its stake in Danaher by 8.9% in the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock valued at $4,177,386,000 after buying an additional 1,487,768 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Danaher by 9.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock valued at $3,656,595,000 after buying an additional 1,334,221 shares during the last quarter. Wellington Management Group LLP lifted its stake in Danaher by 11.2% in the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after buying an additional 1,517,904 shares during the last quarter. Finally, Norges Bank purchased a new stake in Danaher in the fourth quarter valued at approximately $2,177,106,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.